Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.270 -0.030 (-2.31%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday ↗

December 04, 2023

U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.

Via Benzinga

Topics Stocks

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 29, 2023

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS...

Via Benzinga

14 Analysts Have This to Say About Biomea Fusion ↗

July 25, 2023

Via Benzinga

Why Biomea Fusion Stock Is Falling Today? ↗

July 24, 2023

Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with

Via Benzinga

What 18 Analyst Ratings Have To Say About Biomea Fusion ↗

June 26, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 29, 2023

Via Benzinga

Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

November 29, 2023

Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 29, 2023

Via Benzinga

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

November 27, 2023

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

November 16, 2023

BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

November 08, 2023

BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

November 02, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

October 30, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

October 17, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

October 05, 2023

BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

September 28, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

August 31, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

July 31, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 24, 2023

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.

Via Benzinga

BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

July 24, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

June 28, 2023

With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.

Via MarketBeat

Topics Initial Public Offering

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

June 27, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

June 26, 2023

From The Schall Law Firm

Via Business Wire

Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet ↗

June 26, 2023

U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500,...

Via Benzinga

Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 26, 2023

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular...

Via Benzinga

Crude Oil Rises; Carnival Shares Drop After Q2 Results ↗

June 26, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also...

Via Benzinga

Biomea Fusion Stock Is Trading Higher Today - Here's Why ↗

June 26, 2023

Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of new clinical data from the first two cohorts from the Phase 2 portion of its ongoing Phase 1/2 clinical study (COVALENT-111) of BMF-219...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 26, 2023

It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Via InvestorPlace

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3

June 23, 2023

From Biomea Fusion, Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.